Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on X:
”Lipoprotein(a) [Lp(a)] is not just about coronary disease.
Robust genetic and population data confirm Lp(a) as a causal risk factor across multiple vascular beds.
- Peripheral Arterial Disease (PAD): Rising Lp(a) levels show a clear, stepwise association with PAD risk—up to ~3-fold higher risk at extreme concentrations.
- Major Adverse Limb Events (MALE): In patients with PAD, high Lp(a) markedly increases the risk of amputations and repeat revascularizations.
- Abdominal Aortic Aneurysm (AAA): Elevated Lp(a) is consistently associated with higher AAA risk, supported by Mendelian randomization.
- Inflammation matters—but doesn’t negate Lp(a) risk: Lp(a)-associated cardiovascular risk persists independently of hsCRP levels, in both primary and secondary prevention.
Clinical takeaway: Lp(a) identifies residual vascular risk beyond LDL-C and traditional factors—supporting routine measurement and future targeted therapy.
Phase 3 Lp(a)-lowering outcome trials may redefine prevention across coronary and non-coronary vascular disease.
Open Access here.
Article:Lipoprotein(a) in cardiovascular disease with focus on peripheral arterial disease, major adverse limb events, abdominal aortic aneurysms and interaction with low-grade inflammation
Authors: Peter E. Thomas, Signe Vedel-Krogh, Pia R. Kamstrup, Børge G. Nordestgaard
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 28, 2026, 17:03Investing in Education, Prevention, and Lifesaving Research for a Healthier Tomorrow – AHA
-
Feb 28, 2026, 17:00Pamela Gavin: 1 in 10 Americans Live With A Rare Disease – That Is Not Rare, That Is Public Health
-
Feb 28, 2026, 16:59Thomas Rocco Jr: Exploring Agentic AI in Cardiovascular Medicine
-
Feb 28, 2026, 16:50Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease
-
Feb 28, 2026, 16:49Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
-
Feb 28, 2026, 16:46Nicolas Hulscher: Nattokinase Dissolves 84% of Amyloid Microclots In Vitro
-
Feb 28, 2026, 16:46Alfonso Tafur: Preventing Post-Hospitalization Blood Clots Using Precision Tools and Systems
-
Feb 28, 2026, 16:39Anel Karisik: Do Antidepressants Influence Swallowing Recovery After Acute Ischemic Stroke?
-
Feb 28, 2026, 16:38Akinchan Bhardwaj: Targeting SBK2 for Selective Inflammasome Resolution in Atherosclerosis